⁶¹ Cu-NODAGA Prostate-specific Membrane Antigen Imaging and Therapy for Prostate Cancer: Phase 1 Trial of a New Class of ⁶¹ Cu-labeled PET Radiotracers

Q: What type of study is this?

This is a Human Clinical Trial study (also classified as: Phase 1).

Gary A. Ulaner; Jeffrey C. Bassett; Ryan Reddy; Beth Thomsen; D. Reynolds; Khachig J. Jerjian; R.E. Wolfe; David J. Benjamin; Melpomeni Fani; Joseph A. O’Donoghue; Markus Baier; Nicole Schubert; Ben Pais; Francesco De Rose; Leila Jaafar

doi:10.1148/radiol.251151

December 1, 2025Radiology

⁶¹ Cu-NODAGA Prostate-specific Membrane Antigen Imaging and Therapy for Prostate Cancer: Phase 1 Trial of a New Class of ⁶¹ Cu-labeled PET Radiotracers

View at Publisher

Ask AI

Bookmark

Share

Key Points

Cu-NODAGA PSMA imaging demonstrates safety and effectiveness for prostate cancer treatment.
The trial supports the use of innovative Cu-labeled PET radiotracers in oncology.
Analysis of copper-based radiotracers coupled with prostate-specific treatment raises new therapeutic opportunities.
Further exploration is essential to maximize the potential of these novel radiotracers for other malignancies.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Phase 1 trial shows Cu-NODAGA PSMA imaging is safe for prostate cancer, highlighting prospects for novel PET radiotracers.

Abstract

Copper 61 ( 61 Cu)–1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid (NODAGA) prostate-specific membrane antigen (PSMA) imaging and therapy PET is safe and effective for the PSMA-targeted imaging of prostate cancer, opening new opportunities for constructing novel 61 Cu PET radiotracers for multiple malignancies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ulaner et al. (2025) studied this question.

synapsesocial.com/papers/694027632d562116f28fff1a https://doi.org/10.1148/radiol.251151

View at Publisher

Ask AI

Bookmark

Share

⁶¹ Cu-NODAGA Prostate-specific Membrane Antigen Imaging and Therapy for Prostate Cancer: Phase 1 Trial of a New Class of ⁶¹ Cu-labeled PET Radiotracers

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

⁶¹ Cu-NODAGA Prostate-specific Membrane Antigen Imaging and Therapy for Prostate Cancer: Phase 1 Trial of a New Class of ⁶¹ Cu-labeled PET Radiotracers

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading